InMode (INMD -1.62%), a leader in minimally invasive and non-invasive medical aesthetics, released its Q3 2024 earnings on October 30, 2024. The company reported total revenues of $130.2 million, exceeding analyst projections of $126.5 million. Non-GAAP earnings per share (EPS) were $0.70, beating expectations of $0.57. However, a revision of full-year revenue guidance to $410 million - $420 million from an earlier forecast of $430 million - $440 million highlights concerns over macroeconomic uncertainties and demand volatility. Despite these challenges, the quarter showed InMode's potential for strategic recovery and growth.
| Metric | Q3 2024 Results | Analyst Estimate | Q3 2023 Results | % Change YoY |
|---|---|---|---|---|
| Total Revenue | $130.2 million | $126.5 million | $123.1 million | 5.8% |
| Non-GAAP EPS | $0.70 | $0.57 | Not provided | N/A |
| Net Income (GAAP) | $51.0 million | N/A | $46.5 million | 9.7% |
| Gross Margins (GAAP) | 82% | N/A | 84% | -2.4% |
Source: Analyst estimates for the quarter provided by FactSet.
InMode's Business Overview
InMode is renowned for its proprietary radiofrequency-based technologies that enable less invasive aesthetic procedures. These technologies place InMode at the forefront of innovation in the medical aesthetics industry. Its product range spans liposuction, skin tightening, and body contouring. This variety helps weather market fluctuations and sustain a competitive edge.
In recent years, InMode has focused on diversifying its product portfolio to mitigate risk and expand its market reach. The company has faced a mixed quarter, balancing cost management with growth challenges. A significant part of its current focus is on enhancing proprietary technologies and geographical expansion, both considered crucial success factors for future growth.
Highlights of Q3 2024
Despite facing macroeconomic issues, InMode's Q3 revenue beat expectations by generating $130.2 million. A substantial portion, $31.9 million, came from fulfilling pre-orders rather than organic sales growth. This highlights potential concerns over the sustainability of future revenue growth. Non-GAAP EPS of $0.70, surpassing the $0.57 estimate, reflects robust cost controls primarily through effective sales and marketing strategies.
On the product front, InMode successfully launched new platforms such as IgniteRF and Optimus Max, alongside securing FDA clearance for Morpheus8. However, consumables and service revenues saw an 11% decline compared to the previous year, suggesting challenges in maintaining demand within some segments amid market fluctuations.
Capital equipment sales in the U.S. significantly increased, but fell internationally. Operating margins saw pressure due to increased operational expenses, while geopolitical tensions, particularly in Israel, have impacted supply chains, further stressing production and financial results.
InMode acknowledged these dynamics by revising its full-year guidance, lowering expected revenue by approximately 5% to a new range of $410 million - $420 million. This revision highlights challenges in maintaining growth amid broader market pressures and uncertainties.
Looking Ahead
InMode projects a cautious financial outlook, with non-GAAP gross margins expected to remain between 81% and 82%. Non-GAAP income from operations is anticipated to range from $140 million to $145 million. The unchanged EPS guidance suggests reliance on share repurchases to stabilize earnings. Investors should watch how market conditions evolve, especially with pre-orders and product innovations as key focus areas.
Management remains committed to expanding its global footprint, notably into markets like Europe and Japan, which is vital for mitigating U.S. market challenges. Continued investment in research and development aims to sustain InMode's leading position in technological advancements and market expansion strategies.
